Amylyx Pharmaceuticals In...

NASDAQ: AMLX · Real-Time Price · USD
8.01
-0.40 (-4.76%)
At close: Aug 15, 2025, 1:07 PM

Amylyx Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
87.37M 380.79M 22.23M 285K
Cost of Revenue
124.63M 25.44M 2.99M 52K
Gross Profit
-37.26M 355.35M 19.24M 233K
Operating Income
-314.73M 38.8M -201.34M -82.69M
Interest Income
13.81M 16.16M 4.29M 36K
Pretax Income
-302.14M 54.3M -197.6M -87.93M
Net Income
-301.74M 49.27M -198.38M -87.88M
Selling & General & Admin
114.33M 188.36M 127.13M 38.93M
Research & Development
104.08M 128.19M 93.45M 44.04M
Other Expenses
141.53M n/a n/a -285K
Operating Expenses
359.95M 316.54M 220.58M 82.69M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a 9.5M 4.4M n/a
Cost & Expenses
402.1M 341.98M 223.57M 82.69M
Income Tax Expense
-393K 5.03M 774K -52K
Shares Outstanding (Basic)
68.14M 67.23M 66.51M 57.86M
Shares Outstanding (Diluted)
68.14M 69.99M 66.51M 57.86M
EPS (Basic)
-4.43 0.73 -2.98 -1.52
EPS (Diluted)
-4.43 0.70 -2.98 -1.52
EBITDA
-290.98M 39.89M -200.85M -82.64M
EBIT
-291.88M 38.8M -201.34M -82.69M
Depreciation & Amortization
904K 1.09M 487K 52K